BC Week In Review | Feb 8, 2016
Clinical News

Anti-VEGF/Ang2 Nanobody: Phase I started

Boehringer began a dose-escalation Phase I trial to evaluate BI 836880 in patients. The trial start triggered a EUR8 million ($8.7 million) milestone payment to Ablynx from Boehringer under a 2007 deal to use Ablynx’s...
Items per page:
1 - 1 of 1